PK/PD relationship of the monoclonal anti-BAFF antibody tabalumab in combination with bortezomib in patients with previously treated multiple myeloma: comparison of serum M-protein and serum Free Light Chains as predictors of Progression Free survival

Author(s): P. Chanu, R. Bruno, L. Claret, D. B. Radtke, S. P. Carpenter, J. E. Wooldridge, D. M. Cronier

Learn More LinkedIn Twitter Facebook Email